{"protocolSection": {"identificationModule": {"nctId": "NCT05514054", "orgStudyIdInfo": {"id": "18459"}, "secondaryIdInfos": [{"id": "J2J-MC-JZLH", "type": "OTHER", "domain": "Eli Lilly and Company"}, {"id": "2022-501007-28", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Eli Lilly and Company", "class": "INDUSTRY"}, "briefTitle": "A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer", "officialTitle": "EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence", "acronym": "EMBER-4"}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Eli Lilly and Company", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years."}, "conditionsModule": {"conditions": ["Breast Neoplasms"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 6000, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Imlunestrant", "type": "EXPERIMENTAL", "description": "Imlunestrant administered orally.", "interventionNames": ["Drug: Imlunestrant"]}, {"label": "Investigator's Choice of Endocrine Therapy", "type": "ACTIVE_COMPARATOR", "description": "Investigator's choice of tamoxifen, anastrozole, letrozole, or exemestane administered per local approved label.", "interventionNames": ["Drug: Tamoxifen", "Drug: Anastrozole", "Drug: Letrozole", "Drug: Exemestane"]}], "interventions": [{"type": "DRUG", "name": "Imlunestrant", "description": "Administered orally.", "armGroupLabels": ["Imlunestrant"], "otherNames": ["LY3484356"]}, {"type": "DRUG", "name": "Tamoxifen", "description": "Administered per local approved label.", "armGroupLabels": ["Investigator's Choice of Endocrine Therapy"]}, {"type": "DRUG", "name": "Anastrozole", "description": "Administered per local approved label.", "armGroupLabels": ["Investigator's Choice of Endocrine Therapy"]}, {"type": "DRUG", "name": "Letrozole", "description": "Administered per local approved label.", "armGroupLabels": ["Investigator's Choice of Endocrine Therapy"]}, {"type": "DRUG", "name": "Exemestane", "description": "Administered per local approved label.", "armGroupLabels": ["Investigator's Choice of Endocrine Therapy"]}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Have a diagnosis of ER+, HER2- early-stage, resected, invasive breast cancer without evidence of distant metastasis.\n* Participants must have received at least 24 months but not more than 60 months of any adjuvant ET, from time of adjuvant ET initiation.\n* Participants may have received (neo) adjuvant chemotherapy and/or targeted therapy with a CDK4/6- or PARP- inhibitor.\n* Must have an increased risk of disease recurrence based on clinical-pathological risk features.\n* Have a Performance Status of 0 or 1 on the Eastern Cooperative Oncology Group scale.\n* Have adequate organ function.\n\nExclusion Criteria:\n\n* Have any evidence of metastatic disease (including contralateral ALN) or inflammatory breast cancer at primary breast cancer diagnosis.\n* Participants with more than a 6-month consecutive gap in therapy during the course of prior adjuvant ET.\n* Participants who have completed or discontinued prior adjuvant ET \\>6 months prior to screening.\n* Participants with a history of previous breast cancer are excluded, with the exception of ipsilateral DCIS treated by locoregional therapy alone \u22655 years ago.\n* Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 180 days after the last dose of study intervention.\n* Participant has previously received ET of any duration for breast cancer prevention (tamoxifen or AIs) or raloxifene.\n* Participants with a history of any other cancer.\n* Have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", "role": "CONTACT", "phone": "1-317-615-4559", "email": "clinical_inquiry_hub@lilly.com"}], "overallOfficials": [{"name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", "affiliation": "Eli Lilly and Company", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"seeAlsoLinks": [{"label": "A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)", "url": "https://trials.lilly.com/en-US/trial/356295"}]}}, "hasResults": false}